Posts

The effect of administration media on palatability and ease of swallowing of multiparticulate formulations

Abstract

Multiparticulate formulations based on pellets, granules or beads, could be advantageous for paediatrics, geriatrics and patients with swallowing difficulties. However, these formulations may require suitable administration media to facilitate administration. The aim of this work was to investigate the effect of administration media properties on palatability and ease of swallowing of multiparticulates. A range of vehicles were developed using xanthan gum (XG) and carboxymethyl cellulose (CMC) as model hydrocolloids. Such vehicles were prepared at three consistency levels (Level 1 – ‘syrup’, Level 2 – ‘custard’ and Level 3 – ‘pudding’) to investigate the effect of viscosity on their performance as administration media. A randomised, single-blind sensory evaluation study was carried out in thirty healthy adult volunteers using microcrystalline cellulose pellets as model multiparticulates, dispersed in the hydrogels (and water as control) at a concentration of 250 mg in 5 ml. Samples were evaluated using 5-point scales. The use of hydrogels as administration media improved a range of sample attributes compared to water formulations, including appearance, taste, mouthfeel, ease of swallowing and residue in the mouth (all improved by ca. 0,5 points) and oral grittiness perception (improved by ca. 1 point). Polymeric hydrogels thickened to medium consistency (Level 2, XG 0.5% and CMC 1.0% w/v) demonstrated the best performance.

Reference

Article: “The effect of administration media on palatability and ease of swallowing of multiparticulate formulations”

Authors: Felipe L. Lopez, Terry B. Ernest, Mine Orlu, and Catherine Tuleu.

First published: International Journal of Pharmaceutics 2018, 551(1–2) 67-75; https://doi.org/10.1016/j.ijpharm.2018.08.021

1. Introduction

Multiparticulate formulations, in the form of pellets, granules or beads, offer a range of advantages over conventional tablets and capsules, such as ease of swallowing, flexible dose titration, and suitability for taste-masking and controlled-release (Lopez et al., 2015). They are considered a flexible solid dosage form for the delivery of drugs to a broad range of patients, including paediatrics, geriatrics and patients with swallowing difficulties. However, previous studies suggest that grittiness and rough mouthfeel perception might be a barrier to palatability and patient acceptability (Kimura et al., 2015, Lopez et al., 2018, Lopez et al., 2016). A potential solution to overcome palatability and acceptability issues could be co-administration with a suitable vehicle (i.e. sprinkle), which could help to conceal the presence of multiparticulates. Some drug products that contain multiparticulates within a capsule or sachet indicate in the labelling that the internal beads can be sprinkled on soft foods for their administration (FDA, 2012). Commercial examples include Depakote® sprinkle capsules (divalproex sodium), Creon® capsules (pancrelipase), Granupas® gastro-resistant granules in sachets (para-aminosalicylic acid) and Cipla’s lopinavir/ritonavir pellets in capsules (Hanning et al., 2016, Ternik et al., 2017). Typical vehicles recommended for products labelled for sprinkle include apple sauce and yogurt that provide both flavour and viscosity to facilitate administration and improve patient acceptability (Ternik et al., 2017).

Studies comparing sprinkle formulations to liquid dosage forms in children have commonly showed preference for the solid over the liquid form. A range of studies showed acceptance of iron supplement sprinkles and preference for these compared to oral drops in children with anaemia (Adu-Afarwuah et al., 2008, Geltman et al., 2009, Zlotkin et al., 2003). Likewise, studies involving children suffering from epilepsy consistently showed preference for sprinkle formulations over syrup (Cloyd et al., 1992, Motte et al., 2005, Verrotti et al., 2012). In a recent study, children showed preference for sprinkles over syrup after 12-week antiretroviral therapy; 72% of children below 12 months and 64% of children between 1 and 4 years preferred the multiparticulate dosage form. For those preferring syrups, key issues with sprinkles were problems masking the pellets with food and food refusal, and concerns about not giving the whole dose. However, multiparticulates overcome the storing and transporting issues of syrups (Kekitiinwa et al., 2016).

Medicines are known to be mixed with liquid and semi-solid foodstuff to allow administration in clinical practice (Akram and Mullen, 2015, Akram and Mullen, 2012). However, this is not without the risks that mixing medication with foodstuff could alter bioavailability and introduce poor control over dose intake (EMA, 2013). Therefore, when co-administration of medicines and foodstuff is recommended in the package leaflet, the potential impact on patient acceptability, dosing accuracy, compatibility and drug bioavailability of the proposed vehicle(s) must be investigated (EMA, 2013). This task becomes very impractical when medicines can be mixed with a range of foods with different composition and physical properties (e.g. rheology, pH, ionic strength) (Kersten et al., 2016). The development of a standard pharmaceutical vehicle, rationally designed and fit for purpose, could facilitate such investigations. This vehicle could be manufactured by industry and provided with the finished drug product (although this would increase the overall cost of the product) or it could be compounded in a pharmacy (Kluk and Sznitowska, 2014). Investigation into swallowing aids for the administration of oral solid formulations have been the focus of previous research, with some products already in the market in the form of sprays, pastes or jellies (Bunupuradah et al., 2006, Diamond and Lavallee, 2010, Yoshida et al., 2011).

The rheological properties of the administration media require special consideration. Thick fluids are known to exhibit prolonged oral transit times than thinner fluids, which can be used in the management of patient with dysphagia (Soares et al., 2015). Conversely, greater efforts are required to manipulate in the mouth and swallow thick fluids compared to thin ones (Ong et al., 2018, Steele et al., 2015). Consequently, overly thick liquids may increase the risk of post-swallow residue in the mouth and pharynx, especially for patients with reduced tongue or pharyngeal muscle strength (Steele et al., 2015). Newtonian fluids have also been reported to require greater effort in oral processing and swallowing than shear thinning fluids (Steele et al., 2015). In addition, the rheology of the vehicle also affects its palatability, with organoleptic attributes often reported to worsen as the consistency of the fluid increases (Garcia et al., 2005, Ong et al., 2018). Therefore, it is imperative that the rheological and sensory properties of the vehicle are adequately characterised.

The use of a suitable vehicle could facilitate administration of multiparticulates by preventing fast sedimentation, improving palatability and reducing the risk of aspiration or choking often associated with this dosage form design (Walsh et al., 2018). Development of media for the administration of multiparticulates and evaluation of its effect on palatability has been the focus of two recent studies (Kluk and Sznitowska, 2014, Lopez et al., 2016), both of which concluded that the use of polymeric hydrogels as administration media could help conceal the presence of particles, reducing oral grittiness perception. However, both studies focussed on a swirl and spit methodology, which overlooks other important sample attributes such as ease of swallowing. Moreover, neither of those studies investigated the palatability of the liquid vehicles alone, which limited their understanding on the effect of the palatability of the vehicle on the overall palatability and acceptability of the final formulations.

The aim of this work was to develop liquid vehicles for the administration of multiparticulates and to investigate the effect of the administration media properties on palatability and ease of swallowing of multiparticulate formulations. Administration media were developed using xanthan gum (XG) and carboxymethyl cellulose (CMC) as model hydrocolloids. The rheological properties of the hydrocolloids were characterised to investigate the effect of consistency and shear thinning behaviour on their performance as administration media. Palatability attributes and ease of swallowing of the vehicles alone and formulations containing model multiparticulates were evaluated in healthy volunteers.

2. Materials and methods

2.1. Materials

Microcrystalline cellulose pellets (CELLETS® 200 and CELLETS® 700) were provided by Pharmatrans Sanaq (Basel, Switzerland). Xanthan gum (“XG”, Xantural 180, 1% gum in 1% KCl aqueous solution: 1200–1600 cP) was supplied by CP Kelco (Leatherhead, Surrey, UK); sodium carboxymethyl-cellulose (“CMC”, Blanose 7HF-PH, 1% aqueous solution: 1500–2500 cP) was provided by Ashland (Covington, Kentucky, USA); and vanillin was procured from Sigma-Aldrich (Irvine, Ayrshire, UK).

2.2. Preparation of administration media

Polymeric hydrogels in the range of 0.15–1.50% (w/v) were prepared by slow addition of hydrophilic polymer (XG or CMC) into 100 ml of water under continuous stirring at room temperature. Previous research indicate that some hydrocolloids may impart a noticeable foreign taste or off-flavour to water and other liquid vehicles (Matta et al., 2006, Ong et al., 2018, Pelletier, 1997, Saha and Bhattacharya, 2010). For this reason, a small amount of vanillin (0.1% w/v) was added to mask any potential taste and smell of the polymers which could negatively impact results. Samples were left stirring overnight to ensure complete polymer hydration and stored in the refrigerator at 5 ± 0.5 °C. Samples were allowed to equilibrate to room temperature before testing.

For the sensory evaluation study, the viscosity of the XG and CMC vehicles were targeted to meet the International Dysphagia Diet Standardisation Initiative (IDDSI) descriptors (Cichero et al., 2017, IDDSI, 2015). According to this framework, Level 1 fluids are “thicker than water but flow through a teat/nipple and straw”, Level 2 fluids “require effort to drink through a straw and flow quickly off a spoon” and Level 3 fluids are “difficult to suck through a straw and pour slowly off a spoon”.

2.3. Rheological characterisation

A Bohlin CVO rotational rheometer system (Malvern Instruments Ltd, Malvern, UK) was used to investigate the flow properties of the samples using a cone and plate geometry (40 mm diameter, 4° angle; gap size adjusted to 250 µm). A shear sweep measurement mode was employed, whereby the shear rate of the sample was advanced across the range of 0.1–200 s−1, with ascendant logarithmic progression. The temperature of the samples was maintained at 25 ± 0.2 °C throughout testing. This procedure was repeated three times for each sample.

The resulting data (shear rate vs. shear stress) was fitted to the power law model (Eq. (1)) to describe the flow properties of the samples:(1)σ=Kγnwhere σ is the shear stress (Pa), γ is the shear rate (1/s), K is the consistency index (Pas), and n is the flow behaviour index (dimensionless). The consistency index (K) corresponds to the viscosity at a shear rate of 1 s−1; whereas the flow behaviour index (n) provides an indication of the deformation behaviour, where a value of 1 indicates Newtonian behaviour, 0–1 indicates shear-thinning behaviour and values greater than 1 indicate shear-thickening (O’Leary et al., 2010). In addition, the apparent viscosity at 50 s−1 (ƞ at 50 s−1), a reference shear rate for oral processing and swallowing, and the apparent viscosity at 0.1 s−1 (ƞ at 0.1 s−1), a reference shear rate of the sample at rest, were measured by the rheometer along the ascendant shear ramp.

2.4. Sedimentation experiments

The ability of the administration media to maintain multiparticulates in suspension was calculated based on sedimentation experiments. A sample containing 500 mg of CELLETS® and 50 ml of administration media was filled into a 50-ml graduated plastic tube. The tube was turned upside down until homogeneous dispersion of the particles. Then, the sample was left standing and the time taken for CELLETS® to clarify the top 15 ml of the dispersant (approximately one third of the media volume) was determined. This experiment was adapted from that described by Kluk and co-workers (Kluk and Sznitowska, 2014). Experiments were repeated using multiparticulates of two extreme particle sizes, CELLETS® 200 (200–355 µm) and CELLETS® 700 (700–1000 µm), to account for the effect of particle size on sedimentation. The experiment was conducted in triplicate.

2.5. Sensory evaluation study

2.5.1. Study design

Thirty healthy adult volunteers (aged 19–33 years, average 23.2 ± 4.4 years; 21 females) were enrolled in a randomised, single-blind, single-centre, 3-treatment, crossover sensory evaluation. The study was approved by UCL Research Ethics Committee (Project ID: 4612-011). All participants received a detailed information sheet and provided written consent to participate in the study. The study was conducted in three sessions taken place on three separate days. On each day, participants tested samples of liquid vehicles without particles (T1: ‘no particles’), with 200–355 µm particles (T2: ‘smaller particles’) and with 700–1000 µm particles (T3: ‘larger particles’). Participants were divided into six groups to ensure that all possible sequence orders between treatments were considered. In each session, participants were handed eight samples, including XG and CMC samples and water as a control (Table 1), in a randomised order.

table-1

Table 1. List of liquid vehicles assessed in sensory evaluation experiments.

For samples containing multiparticulates, 250 mg of solid particles were pre-dispersed in the administration media (approximately 3 ml, for a total volume of 5 ml) using a spatula immediately before administration. Microcrystalline cellulose pellets used in this investigation were non-disintegrating in water or in the mouth. Samples were provided onto 5-ml plastic medicine spoons that were handed to participants of the study. During the evaluation of the samples, participants had free access to spring water to complete sample intake and clean their palate. To minimise subject discomfort and carryover effect 5–10-minute intervals were respected between samples.

2.5.2. Evaluation tool and outcome measures

A digitalized questionnaire (Qualtrics.com) was used for data collection. Immediately after swallowing the sample, volunteers were asked to rate several sample attributes, including appearance, ease of swallowing, mouth-feel and taste, using a 5-point hedonic scale (1 – extremely liked, 5 – extremely disliked). In addition, the feeling of particles in the mouth during sample intake (i.e. grittiness perception) and the feeling of particles in the mouth after sample intake and after rinsing their mouth with water (i.e. residue in mouth) was assessed using a 5-point magnitude scale (1 – not perceptible, 5 – extremely perceptible). Participants could also provide voluntary feedback of each sample attribute using their own words.

2.5.3. Data analysis

The different categories of the 5-point scales were assigned numeric scores (1–5) from lowest to highest stimuli perception, respectively. Statistical analysis was performed using the non-parametric Kruskal-Wallis one-way analysis of variance followed by Dunn’s test as post hoc for pairwise comparison, both with a 95% confidence level. Minitab 17 (Minitab Inc., State College, Pennsylvania, USA) was used for data analysis.

3. Results and discussion

3.1. Development of administration media for multiparticulates

3.1.1. Rheological properties

The rheological properties of the administration media require especial attention as these will have an impact on several critical quality attributes, such as suspendability and palatability (particularly appearance and mouth-feel). XG and CMC were selected as model excipients to develop polymeric hydrogels for the administration of multiparticulates, being Generally Regarded As Safe (GRAS) excipients commonly used in oral formulations.

The rheological properties of XG and CMC hydrogels were investigated as a function of the hydrocolloid concentration (Table 2). The consistency index of XG and CMC-based polymeric hydrogels increased as the hydrocolloid concentration increased, as it can be expected. The increase in viscosity was more pronounced for XG than it was for CMC, revealing the higher ‘thickening power’ of XG. In addition, XG hydrogels exhibited a strong shear thinning behaviour whereas CMC hydrogels showed a much lower degree of shear thinning; the flow behaviour index (n-value) of XG-based hydrogels was lower than that of CMC-based hydrogels throughout the range of concentrations tested.

table-2

Table 2. Rheological characteristics of XG and CMC hydrogels prepared at concentrations 0.15–1.50% w/v.

The contrasting rheological characteristics of XG and CMC made them ideal candidates to investigate the effect of shear thinning behaviour on their performance as administration media for the administration of multiparticulates. Previous research indicate that Newtonian fluids require greater effort in oral processing and swallowing than shear thinning fluids (Steele et al., 2015). However, it could be hypothesised that shear thinning fluids would be less effective in ‘masking’ the presence of particles since the viscosity of these fluids will decrease under the relatively high shear rates experienced during oral processing (50–300 s−1) (Steele et al., 2015).

3.1.2. Ability to maintain multiparticulates in suspension

An ideal vehicle should be able to maintain multiparticulates in suspension from dispersion of the particles in the media until administration. Sedimentation time of multiparticulates in polymeric hydrogels was determined by measuring the time lapse between homogeneous dispersion of multiparticulates and clearance of the top layer of the liquid vehicle. Results of sedimentation time as a function of the media viscosity are summarised in Table 3. The time needed for manipulation and administration of a medicine is usually less than 5 min but can take longer than 10 min in some cases (Ruiz et al., 2016), thus appropriate administration media should maintain multiparticulates in suspension for at least 10–15 min.

table-3

Table 3. Sedimentation time (minutes) of CELLETS® 200 and CELLETS® 700 in XG and CMC hydrogels.

Sedimentation time increased with increasing viscosity of the media and decreased with increasing size of the multiparticulates, in accordance to Stoke’s law. XG hydrogels prepared at 0.25% w/v would be sufficient to maintain both 200–355 and 700–1000 µm particles in suspension for at least 10–15 min, whereas a higher concentration of CMC (1.00% w/v) would be required to maintain the larger particles in suspension for the same time. The lower concentration of XG required to maintain multiparticulates in suspension could be expected based on its stronger thickening power and its shear thinning character, which means that the viscosity of XG hydrogels at low shear rates (i.e. shear rates relevant during sedimentation) is higher than that of CMC hydrogels.

3.2. Sensory evaluation studies

3.2.1. Liquid vehicles without multiparticulates

Participants of the sensory evaluation study tested liquid vehicles without multiparticulates in one of the three sessions of the study. The analysis of liquid vehicles without multiparticulates was performed in order to gain fundamental understanding of the properties of the liquid vehicles, such as appearance, mouthfeel, taste and ease of swallowing.

All samples evaluated received average appearance ratings in the neutral to positive range of the scale, except for XG L3 (average appearance rating = 3.17). According to participants responses to hedonic scales, the appearance of XG hydrogels was worse than the appearance of water and CMC hydrogels (p < 0.001), as shown in Fig. 1. This was adscribed to the opaque appearance of XG hydrogels (in contrast with the transparent aspect of water and CMC hydrogels), as supported by anecdotal feedback provided by the participants: e.g. “I personally prefer when the sample is limpid, this one was a bit opaque and it gives you an idea of dirt” (Participant 11, XG L3). Appearance ratings worsened as the consistency level increased. This indicates that the appearance of very thick samples (which retain their shape when placed on a spoon) was considered less appealing than thinner fluids.

swallowing of multiparticulate formulations_fig-1

Fig. 1. Interval plot for appearance, mouthfeel, taste and ease of swallowing of different liquid vehicles. Markers represent the population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the worst possible rating) and bars show the 95% CI for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3).

The taste of all liquid vehicles evaluated received average ratings between 2 and 3 (range: 2.33–2.63; XG L1 – Water), which indicates acceptable neutral taste (Fig. 1). The very small differences between samples confirmed that the level of vanillin used was appropriate to mask any potential foreign taste from the polymer without having a significant impact on results (as it was intended). However, the fact that average ratings for taste were closer to the centre of the scale than to the positive end of the scale may indicate participants’ expectations of a more intense, sweetened or flavoured taste for samples intended as a medicinal product. This was reinforced by voluntary feedback; e.g. “if this had added sugar/sweetener it would be a more enjoyable medicine to take” (P05, CMC L3).

Mouthfeel ratings of XG and CMC hydrogels worsened as the consistency of the sample increased, revealing preference for thinner vehicles (Fig. 1). This is consistent with previous research which reported that thinner fluids are perceived as less viscous, less adhesive and easier to manipulate in the mouth than thicker fluids (Ong et al., 2018). However, all samples received average ratings in the neutral to positive range of the scale (range: 1.67–2.90), suggesting all vehicles prepared had an acceptable mouthfeel to be used as media for the administration of multiparticulates. CMC hydrogels received slighly worse mouthfeel ratings than XG samples, which was attributed to a “greasy” or “oily” feeling in the mouth, as reported by the volunteers. The mouth-coating texture of CMC hydrogels has been reported in previous research and attributed to its low degree of shear thinning (high n-value) (Cho et al., 2015, Szczesniak and Farkas, 1962). On the contrary, xanthan gum samples have been perceived as less adhesive and easier to manipulate in the mouth (Ong et al., 2018). Nevertheless, mouthfeel differences between XG and CMC vehicles were not statistically significant, despite their contrasting rheological profiles. The inability to clearly identify preference between samples can be explained by consumers, including patients, having different criteria for personal preferences (Matta et al., 2006).

All samples evaluated were considered ‘easy to swallow’ by healthy volunteers, receiving average ratings in the neutral to positive range of the scale (range: 1.07–2.57). However, samples were considered relatively more difficult to swallow as the consistency level increased (p < 0.001), as depicted in Fig. 1. This can be attributed to the greater effort required to convey thicker fluids through the oral cavity and greater effort required for the throat muscles to swallow thicker fluids (Ong et al., 2018). In their open-ended feedback, participants described the need to swallow repetitively to achieve full ingestion of thicker samples; e.g. “the sample is very viscous and is difficult to swallow, it remains in my mouth after swallowing a few times” (P22, CMC L3). This is in line with previous research as thicker liquids have been shown to increase the risk of post-swallow residue in the mouth and pharynx (Steele et al., 2015). It is also well established that fluids with higher viscosity exhibit prolonged oral transit times as compared to thinner fluids such as water (Soares et al., 2015). Moreover, the ratings of ease of swallowing indicate that XG hydrogels were slightly easier to swallow than CMC hydrogels (p < 0.018), which was supported by anecdotal feedback; e.g. “this sample (CMC L2) is more difficult than the previous one (XG L2) in swallowing it as a whole, as it remains in my mouth after the first swallow” (P10, CMC L2). This can be explained by the stronger shear thinning behaviour of XG hydrogels. Shear thinning fluids can be expected to be easier to swallow due to lower resistance to flow under shear (Ong et al., 2018, Steele et al., 2015).

3.2.2. Multiparticulates dispersed in liquid vehicles

The appearance of multiparticulate samples dispersed in different vehicles received average ratings around the neutral range of the scale (range: 2.70–3.40), as shown in Fig. 2. The size of the multiparticulates had no influence on the ratings of appearance (p = 0.074), whereas the vehicle used had a significant impact on the appearance of the final formulation (p < 0.001). The appearance of samples dispersed in polymeric hydrogels (2.96 for XG and 2.77 for CMC hydrogels, on average) was considered better than that of samples dispersed in water (3.33 with and 3.40 without vanillin). This was explained by the more homogenous appearance of samples dispersed in thickened vehicles as compared to multiparticulates dispersed in water. Multiparticulates precipitated very quickly in water, due to its very low viscosity, leading to heterogenous samples with particles settled down on the bottom of the spoon. On the contrary, CELLETS® remained homogeneously dispersed in thicker hydrogels, which was considered a positive feature by the volunteers. Moreover, samples prepared in XG vehicles thickened to the highest consistency were rated more negatively than samples dispersed in other hydrogels, which can be expected based on the negative ratings of appearance received by this vehicle when evaluated on its own.

swallowing of multiparticulate formulations_fig-2

Fig. 2. Interval plot for appearance, taste, mouthfeel and ease of swallowing as a function of the vehicle used as suspending media and the size of the dispersed multiparticulates: 200–355 µm (CELLETS® 200) or 700–1000 µm (CELLETS® 700). Markers represent the population mean for the hedonic ratings (where 1 is the best possible rating and 5 is the worst possible rating) and bars show the 95% CI for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3).

The taste of the samples worsened when multiparticulates where added into the formulation and when the multiparticulate size increased (Fig. 2); from 2.44 on average without presence of multiparticulates to 2.63 and 2.89 on average with smaller and larger multiparticulates, respectively. In addition, the taste of formulations with vanilla flavour was deemed better than the taste of samples prepared with pure water (p < 0.001). On the contrary, no significant differences were found between XG and CMC samples in terms of taste which, again, confirmed the successful masking of any potential inherent taste of the polymer by addition of a small quantity of vanillin. Although microcrystalline cellulose pellets are expected to be tasteless, negative taste ratings in hedonic scales have been previously reported and attributed to the poor mouthfeel of the formulation (Lopez et al., 2018). This can be explained by a common cognitive bias in sensory evaluation by which perception of a salient attribute influences the ratings of other (independent) sample attributes (Clark and Lawless, 1994).

The mouthfeel of multiparticulates dispersed in liquid vehicles also received average ratings around the neutral range of the scale (Fig. 2). Both the size of the multiparticulates and the vehicle used to disperse them had a significant impact on mouthfeel of the final formulation (p = 0.001 and p < 0.001, for size and vehicle, respectively). The mouthfeel of samples containing smaller multiparticulates was on average 0.30 points better than that of samples containing larger multiparticulates. An increasing grittiness sensation or rough mouthfeel with increasing size of the multiparticulates have also been reported on previous studies (Kimura et al., 2015, Kluk and Sznitowska, 2014, Lopez et al., 2018, Lopez et al., 2016). In terms of the vehicle used, participants showed preference for samples dispersed in thickened vehicles over samples dispersed in water. In addition, participants preferred the samples with low and middle-range consistencies (Level 1 and Level 2) over the extremely thick ones (Level 3). According to the participants of the study, those samples achieved a good balance by “concealing the presence of particles in the mouth” but not being too thick (which has a detrimental impact on mouthfeel). Samples thickened to Level 1 and Level 2 consistencies were rated on average 0.62 and 0.54 points better than water, respectively, whereas samples with Level 3 consistency were rated only 0.34 points better than water, on average.

As depicted in Fig. 2, swallowing of multiparticulates was considered more difficult with increasing particle size, from 2.36 on average for smaller multiparticulates to 2.91 on average for larger multiparticulates (p < 0.001). Multiparticulates dispersed in polymeric hydrogels were easier to swallow than multiparticulates dispersed in water (by approximately 0.50 points), irrespectively of the size of the particles. Both XG and CMC hydrogels were similarly efficient in facilitating swallowing of the multiparticulates (2.52 and 2.49 on average, respectively). Therefore, no significant differences were found between XG and CMC hydrogels in terms of ease of swallowing when administered with multiparticulates, despite their different rheological properties and the differences found when administered without multiparticulates. This might indicate that the sensory properties of the samples were dominated by the presence of particles in suspension at relatively high concentration (Mueller et al., 2010), thus differences between vehicles became negligible. The rheological properties of the samples could be dramatically affected by addition of multiparticulates; the inclusion of the solid particles is expected to produce and increase in consistency and in shear thinning behaviour (Mueller et al., 2010). In agreement with the results for mouthfeel perception, participants showed preference for swallowing samples with thin and middle-range consistencies (Levels 1 and 2) as opposed to thicker samples. These samples performed best at “carrying the particles together” as a bolus and “providing cushioning”, facilitating swallowing, while not being too thick to “linger around” in the oral cavity for long. The contrast between samples of different consistency was reported in open-ended responses; e.g.: “the liquid in this sample was too runny and was unable to carry the particles along with it, so the liquid part was consumed first, leaving behind the solid part of the sample” (P02, CELLETS® 200 in Water); or “I feel that this sample has the correct viscosity that is able to hold the particles together and is able to be easily swallowed” (P10, CELLETS® 200 in XG L1).

As discussed above, grittiness perception increased with increasing size of the multiparticulates (p < 0.001) in agreement with previous studies (Kimura et al., 2015, Kluk and Sznitowska, 2014, Lopez et al., 2018, Lopez et al., 2016); samples of smaller multiparticulates obtained an average grittiness score of 2.50 compared to 3.31 scored on average by samples containing larger multiparticulates. The feeling of residual particles in the mouth also increased with increasing size of the multiparticulates, 1.67 on average for CELLETS® 200 compared to 2.14 on average for CELLETS® 700 (Fig. 3). Participants ratings of ‘grittiness perception’ confirmed the results obtained for mouthfeel and ease of swallowing in that polymeric hydrogels masked the presence of multiparticulates. Grittiness perception was lower for polymeric hydrogel formulations than for samples dispersed in water by approximately 1.0 point, on average, both for smaller and larger multiparticulates. This was supported by voluntary feedback; e.g. “without a thick solution to act as a lubricant and carry the particles along with it, the ‘grainy’ feeling was enhanced, making it very unpleasant to take” (P02, CELLETS® 200 in water); compared to samples in thickened vehicles, e.g. “it is viscous, but that masks the overall ‘particles feel’, which is good” (P12, CELLETS® 200 in CMC L2). The use of polymeric hydrogels to disperse multiparticulates also reduced the ‘residue in mouth’, i.e. the feeling of particles in the mouth after swallowing (p < 0.001), for multiparticulates of both sizes evaluated. The residual feeling of particles was reduced by approximately 0.5 points on average when using polymeric hydrogels as vehicles, as compared to water.

swallowing of multiparticulate formulations_fig-3

Fig. 3. Interval plot for grittiness and residue of multiparticulates in mouth after swallowing as a function of the vehicle used as suspending media and the size of the multiparticulates: 200–355 µm (CELLETS® 200) or 700–1000 µm (CELLETS® 700). Markers represent the population mean for the 5-point magnitude scale (where 1 is the lowest possible and 5 is the highest possible intensity of the stimulus) and bars show the 95% CI for the mean. Water + v. represents water to which 0.1% w/v vanillin was added; the consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3).

According to the ratings on the 5-point scale, no significant differences were found between XG and CMC hydrogels in their ability to mask the grittiness of particles, either during sample intake or after swallowing of the samples; although the trend suggests that CMC vehicles performed better when using multiparticulates of larger size. As previously discussed, this indicates that the sensory properties of the samples were dominated by the presence of multiparticulates rather than the shear thinning behaviour of the vehicles. Moreover, no significant differences were found between vehicles thickened to different consistency levels based on scale ratings, although anecdotal feedback indicated that thicker hydrogels performed better than thinner vehicles in terms of masking the presence of particles, e.g. “less thick than other samples, thus I can feel the particles when I swallowed it; need to drink water to remove the particles” (P16, CELLETS® 200 in XG L1). Disagreement between grittiness ratings and voluntary feedback suggests that scale ratings were influenced by the overall appreciation of the sample, an issue commonly encountered in sensory evaluation studies (Clark and Lawless, 1994, Prescott et al., 2011). As the concentration of hydrocolloid in de sample increased, the perception of particles decreased but other organoleptic attributes worsened. As such, mouthfeel and grittiness perception were driven by a balance between those opposing phenomena, which explains the similar ratings obtained by samples of different consistency despite their different organoleptic attributes. These findings highlight the multifactorial nature of palatability and mouthfeel perception which poses a challenge to evaluate sample attributes independently (Clark and Lawless, 1994, Popper et al., 2004, Prescott et al., 2011).

The results of these trial are summarised in Fig. 4, where the radar charts show the mean result for each palatability attribute as a function of the size of the multiparticulates and the administration media (water with vanillin, which was used as a control, was excluded from the graphs to aid clarity). The use of polymeric hydrogels as administration media resulted in an overall improvement of the samples: appearance, taste, mouthfeel, ease of swallowing and residue in the mouth improved by ca. 0.5 points, and oral grittiness perception improved by ca. 1 point. Overall, polymeric hydrogels thickened to medium consistency (Level 2) demonstrated the best performance by virtue of their ability to conceal the grittiness of multiparticulates in the mouth and to aid swallowing of the formulation as a bolus, while maintaining a balanced consistency (not too thick) to ensure appropriate mouthfeel. These findings were in line with previous research in the field in that vehicles of very thick consistency tend to be disliked despite their ability to mask the presence of multiparticulates in the formulation (Kluk and Sznitowska, 2014, Lopez et al., 2016). Further investigation of the physicochemical properties of the samples, such as adhesiveness, ductility and lubrication properties could provide a more rigorous insight into the physical drivers for mouthfeel perception (Stokes et al., 2013). Differences in palatability and acceptability can be expected in different sub-sets of the population (Lopez et al., 2018, Mennella et al., 2012), thus future work should investigate the acceptability of these vehicles in paediatrics and patients with swallowing difficulties, those who could benefit the most from these formulations.

swallowing of multiparticulate formulations_fig-4

Fig. 4. Radar chart for appearance, taste, grittiness, mouthfeel, ease of swallowing and residue of multiparticulates in mouth as a function of the vehicle used as suspending media and the size of the multiparticulates: 200–355 µm (CELLETS® 200) or 700–1000 µm (CELLETS® 700). Each palatability item is described by its population mean for the 5-point scale (where 1 is the lowest possible and 5 is the highest possible intensity of the stimulus). The consistency level of XG and CMC hydrogels is described as L1 (Level1), L2 (Level 2) and L3 (Level 3).

4. Conclusion

The use of hydrogels as administration media for multiparticulates improved a range of sample attributes compared to water formulations, including appearance, taste, mouthfeel, ease of swallowing and grittiness perception during and after sample intake. This improvement was apparent for samples containing multiparticulates of both sizes investigated (those over 200 and those over 700 µm). Polymeric hydrocolloids provided ‘cushioning and lubrication’ of the particles and acted as an effective vehicle by ‘carrying the particles together’, concealing the gritty feeling of the multiparticulates and assisting swallowing. Participants also reported that additional intake of water after administration of the gel formulation was beneficial to facilitate swallowing of the full dose of multiparticulates. Polymeric hydrogels thickened to medium consistency (Level 2, XG 0.5% and CMC 1.0% w/v) were preferred over either thinner or thicker vehicles. A balanced consistency reduced the gritty feeling of multiparticulates while not being overly thick, which would hinder sensory attributes. Meanwhile, differences between XG and CMC hydrogels were minimal despite their opposing shear thinning behaviour. These findings suggest that the consistency of the vehicle was an attribute of greater importance than its shear thinning behaviour. However, XG brings the added value of its strong thickening power, requiring very low concentrations to produce hydrogels of adequate consistency. Results of this study indicate that polymeric hydrogels could be used to improve palatability, facilitate swallowing and enhance patient acceptability of multiparticulate formulation.

5. Author contribution statement

Felipe L. Lopez: Methodology, Investigation, Formal Analysis, Visualization, Writing- Original draft preparation. Terry B. Ernest: Funding Acquisition, Conceptualization, Methodology, Supervision, Writing – Review & Editing. Mine Orlu: Funding Acquisition, Conceptualization, Methodology, Supervision, Writing – Review & Editing. Catherine Tuleu: Funding Acquisition, Conceptualization, Methodology, Validation, Supervision, Writing – Review & Editing.

Acknowledgement

The authors are grateful to the EPSRC for providing funding through a studentship within the CDT in Targeted Therapeutics and Formulation Sciences (EPSRC grant: EP/I01375X/1).

Conflict of interest statement

The authors declare no conflict of interest other than their disclosed affiliations and acknowledged funding.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ijpharm.2018.08.021.

License

Creative Commons license CC BY 4.0.

References

Adu-Afarwuah, S., Lartey, A., Brown, K.H., Zlotkin, S., Briend, A., Dewey, K.G., 2008. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. Am. J. Clin. Nutr. 87, 929–938.

Akram, G., Mullen, A.B., 2015. Mixing medication into foodstuffs: identifying the issues for paediatric nurses. Int. J. Nurs. Pract. 21, 125–131. https://doi.org/10.1111/ijn.12222.

Akram, G., Mullen, A.B., 2012. Paediatric nurses’ knowledge and practice of mixing medication into foodstuff. Int. J. Pharm. Pract. 20, 191–198. https://doi.org/10.1111/j.2042-7174.2011.00179.x.

Bunupuradah, T., Wannachai, S., Chuamchaitrakool, A., Intasan, J., Nuchapong, T., Neiss, W., Kramm, K., Pancharoen, C., Burger, D., Ananworanich, J., 2006. Use of tastemasking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. AIDS Res. Ther. 3, 30. https://doi.org/10.1186/1742-6405-3-30.

Cho, H., Yoo, W., Yoo, B., 2015. In: Effect of NaCl Addition on Rheological Behaviors of Commercial Gum-Based Food Thickener Used for Dysphagia Diets, pp. 137–142. https://doi.org/https://doi.org/10.3746/pnf.2015.20.2.137.

Cichero, J.A.Y., Lam, P., Steele, C.M., Hanson, B., Chen, J., Dantas, R.O., Duivestein, J., Kayashita, J., Lecko, C., Murray, J., Pillay, M., Riquelme, L., Stanschus, S., 2017. Development of international terminology and definitions for texture-modified foods and thickened fluids used in dysphagia management: the IDDSI framework. Dysphagia 32, 293–314. https://doi.org/10.1007/s00455-016-9758-y.

Clark, C., Lawless, H.T., 1994. Limiting response alternatives in time-intensity scaling: an examination of the halo-dumping effect. Chem. Senses 19, 583–594. https://doi.org/10.1093/chemse/19.6.583.

Cloyd, J.C., Kriel, R.L., Jones-Saete, C.M., Ong, B.Y., Jancik, J.T., Remmel, R.P., 1992. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. 120, 634–638. https://doi.org/10.1016/S0022-3476(05)82496-5.

Diamond, S., Lavallee, D.C., 2010. Experience with a pill-swallowing enhancement aid. Clin. Pediatr. (Phila) 49, 391–393. https://doi.org/10.1177/0009922809355313. EMA, 2013. Guideline on pharmaceutical development of medicines for paediatric use [WWW Document]. URL  http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf.

FDA, 2012. Guidance for Industry Size of Beads in Drug Products Labeled for Sprinkle Guidance for Industry Size of Beads in Drug Products Labeled for Sprinkle.

Garcia, J.M., Chambers IV, E., Matta, Z., Clark, M., 2005. Viscosity measurements of nectar- and honey-thick liquids: product, liquid, and time comparisons. Dysphagia 20, 325–335. https://doi.org/10.1007/s00455-005-0034-9.

Geltman, P.L., Hironaka, L.K., Mehta, S.D., Padilla, P., Rodrigues, P., Meyers, A.F., Bauchner, H., 2009. Iron supplementation of low-income infants: a randomized clinical trial of adherence with ferrous fumarate sprinkles versus ferrous sulfate drops. J. Pediatr. 154. https://doi.org/10.1016/j.jpeds.2008.11.003.

Hanning, S.M., Lopez, F.L., Wong, I.C.K., Ernest, T.B., Tuleu, C., Orlu Gul, M., 2016. Patient centric formulations for paediatrics and geriatrics: similarities and differences. Int. J. Pharm. 512, 355–359. https://doi.org/https://doi.org/10.1016/j.ijpharm.2016.03.017.
IDDSI, 2015. Detailed Descriptors, Testing Methods and Evidence – Drinks: Levels 0-4 [WWW Document]. URL http://iddsi.org/framework/.

Kekitiinwa, A., Musiime, V., Thomason, M.J., Mirembe, G., Lallemant, M., Nakalanzi, S., Baptiste, D., Walker, A.S., Gibb, D.M., Judd, A., Judd, A., 2016. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antiviral Ther. https://doi.org/10.3851/IMP3054.

Kersten, E., Barry, A., Klein, S., 2016. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children. Pharmazie 71, 122–127. https://doi.org/10.1691/ph.2016.5145.

Kimura, S., Uchida, S., Kanada, K., Namiki, N., 2015. Effect of granule properties on rough mouth feel and palatability of orally disintegrating tablets. Int. J. Pharm. 484, 156–162. https://doi.org/10.1016/j.ijpharm.2015.02.023.

Kluk, A., Sznitowska, M., 2014. Application properties of oral gels as media for administration of minitablets and pellets to paediatric patients. Int. J. Pharm. 460, 228–233.  https://doi.org/10.1016/j.ijpharm.2013.10.052.

Lopez, F.L., Bowles, A., Gul, M.O., Clapham, D., Ernest, T.B., Tuleu, C., 2016. Effect of formulation variables on oral grittiness and preferences of multiparticulate formulations in adult volunteers. Eur. J. Pharm. Sci. 92, 156–162. https://doi.org/10.1016/j.ejps.2016.07.006.

Lopez, F.L., Ernest, T.B., Tuleu, C., Gul, M.O., 2015. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin. Drug Deliv. 12, 1727–1740. https://doi.org/10.1517/17425247.2015.1060218.

Lopez, F.L., Mistry, P., Batchelor, H.K., Bennett, J., Coupe, A., Ernest, T.B., Orlu, M., Tuleu, C., 2018. Acceptability of placebo multiparticulate formulations in children and adults. Sci. Rep. 1–10. https://doi.org/10.1038/s41598-018-27446-6.

Matta, Z., Chambers IV, E., Garcia, J.M., Helverson, J.M.G., 2006. Sensory characteristics of beverages prepared with commercial thickeners used for dysphagia diets. J. Am. Diet. Assoc. 106, 1049–1054. https://doi.org/10.1016/j.jada.2006.04.022.

Mennella, J.A., Finkbeiner, S., Reed, D.R., 2012. The proof is in the pudding: children prefer lower fat but higher sugar than do mothers. Int. J. Obes. 36, 1285–1291. https://doi.org/10.1038/ijo.2012.51.

Motte, J., Pedespan, J.M., Sevestre, M., Chiron, C., 2005. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old. Arch. Pediatr. 12, 1533–1539. https://doi.org/10.1016/j.arcped.2005.07.009.

Mueller, S., Llewellin, E.W., Mader, H.M., 2010. The rheology of suspensions of solid particles. Proc. R. Soc. 466, 1201–1228. https://doi.org/10.1007/BF01432034.

O’Leary, M., Hanson, B., Smith, C., 2010. Viscosity and non-Newtonian features of thickened fluids used for dysphagia therapy. J. Food Sci. 75, E330–E338. https://doi.org/10.1111/j.1750-3841.2010.01673.x.

Ong, J.J.X., Steele, C.M., Duizer, L.M., 2018. Sensory characteristics of liquids thickened with commercial thickeners to levels specified in the International Dysphagia Diet Standardization Initiative (IDDSI) framework. Food Hydrocoll. 79, 208–217. https://doi.org/10.1016/j.foodhyd.2017.12.035.

Pelletier, C.A., 1997. A comparison of consistency and taste of five commercial thickeners. Dysphagia 12, 74–78. https://doi.org/10.1007/PL00009522.

Popper, R., Rosenstock, W., Schraidt, M., Kroll, B.J., 2004. The effect of attribute questions on overall liking ratings. Food Qual. Prefer. 15, 853–858. https://doi.org/10.1016/j.foodqual.2003.12.004.

Prescott, J., Lee, S.M., Kim, K.O., 2011. Analytic approaches to evaluation modify hedonic responses. Food Qual. Prefer. 22, 391–393. https://doi.org/10.1016/j.foodqual.2011.01.007.

Ruiz, F., Vallet, T., Pensé-Lhéritier, A.-M., Aoussat, A., 2016. Standardized method to assess medicines’ acceptability: focus on paediatric population. J. Pharm. Pharmacol. https://doi.org/10.1111/jphp.12547.

Saha, D., Bhattacharya, S., 2010. Hydrocolloids as thickening and gelling agents in food: a critical review. J. Food Sci. Technol. 47, 587–597. https://doi.org/10.1007/s13197-010-0162-6.

Soares, T.J., Moraes, D.P., de Medeiros, G.C., Sassi, F.C., Zilberstein, B., de Andrade, C.R.F., 2015. Oral transit time: a critical review of the literature. Arq. Bras. Cir. Dig. 28, 144–147. https://doi.org/10.1590/S0102-67202015000200015.

Steele, C.M., Alsanei, W.A., Ayanikalath, S., Barbon, C.E.A., Chen, J., Cichero, J.A.Y., Coutts, K., Dantas, R.O., Duivestein, J., Giosa, L., Hanson, B., Lam, P., Lecko, C., Leigh, C., Nagy, A., Namasivayam, A.M., Nascimento, W.V., Odendaal, I., Smith, C.H., Wang, H., 2015. The influence of food texture and liquid consistency modification on swallowing physiology and function: a systematic review. Dysphagia 30, 2–26. https://doi.org/10.1007/s00455-014-9578-x.

Stokes, J.R., Boehm, M.W., Baier, S.K., 2013. Oral processing, texture and mouthfeel: from rheology to tribology and beyond. Curr. Opin. Colloid Interface Sci. 18, 349–359. https://doi.org/10.1016/j.cocis.2013.04.010.

Szczesniak, A.S., Farkas, E., 1962. Objective characterization of the mouthfeel of gum solutions. J. Food Sci. 27, 381–385. https://doi.org/10.1111/j.1365-2621.1962. tb00112.x.

Ternik, R., Liu, F., Bartlett, J.A., Khong, M., Cheng, D., Tan, T., Dixit, T., Wang, S., Galella, E.A., Gao, Z., Klein, S., 2017. Assessment of swallowability and palatability of oral dosage forms in children: report from an M-CERSI pediatric formulation workshop. Int. J. Pharm. https://doi.org/10.1016/j.ijpharm.2017.08.088.

Verrotti, A., Nanni, G., Agostinelli, S., Alleva, E.T., Aloisi, P., Franzoni, E., Spalice, A., Chiarelli, F., Coppola, G., 2012. Effects of the abrupt switch from solution to modified-release granule formulation of valproate. Acta Neurol. Scand. 125, 14–18. https://doi.org/10.1111/j.1600-0404.2011.01568.x.

Walsh, J., Ranmal, S.R., Ernest, T.B., Liu, F., 2018. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int. J. Pharm. 536, 547–562. https://doi.org/10.1016/j.ijpharm.2017.07.017.

Yoshida, M., Hazekawa, M., Haraguchi, T., Uchida, T., 2011. Influence of swallowing Aids on the adsorption and palatability of Kremezin®. Chem. Pharm. Bull. (Tokyo) 59, 434–437. https://doi.org/10.1248/cpb.59.434.

Zlotkin, S., Antwi, K.Y., Schauer, C., Yeung, G., 2003. Use of microencapsulated iron(II) fumarate sprinkles to prevent recurrence of anaemia in infants and young children at high risk. Bull. World Health Organ. 81, 108–115. https://doi.org/10.1590/S0042-96862003000200007.

Enzyme-cleavable methadone prodrugs Innovations in formulation

Enzyme‑cleavable methadone prodrugs: Functionality, Opportunities, and Summary of US20250361205A1

Introduction to Enzyme‑cleavable methadone prodrugs

Enzyme‑cleavable methadone prodrugs represent a novel class of pharmacological agents designed to provide controlled release of methadone only after specific enzymatic activation. These prodrugs attach an enzyme‑cleavable promoiety to the methadone molecule, rendering it inactive until a target enzyme cleaves the linkage in vivo. This mechanism reduces misuse potential and provides more predictable pharmacokinetics compared to conventional methadone formulations. By depending upon specific enzymatic activity, this prodrug design can improve safety and minimize risks associated with inappropriate administration or overdose, while maintaining therapeutic efficacy for opioid dependence or chronic pain management.

Beyond safety, enzyme‑cleavable methadone prodrugs offer opportunities in advanced drug formulation. They enable precise control over the timing and extent of methadone release based on the activity of endogenous enzymes. As a result, formulators can tailor release rates and reduce systemic peaks that commonly contribute to adverse effects or abuse. These prodrugs also permit formulation with excipients or technologies that further modulate release profiles, including multiparticulate systems or coatings. In addition, controlled enzyme activation provides a strategy to optimize oral delivery, enhance patient compliance, and potentially reduce the burden of supervised dosing programs in opioid maintenance therapy.

Summary of this patent

The patent application US20250361205A1 discloses enzyme‑cleavable methadone prodrugs and corresponding methods of use, focusing on prodrugs that deliver methadone through enzymatically‑controlled release. These prodrugs contain a promoiety linked to methadone that requires cleavage by specific enzymes, such as digestive proteases, before the active opioid is liberated. By requiring enzymatic cleavage followed by intramolecular cyclization to release active methadone, the design significantly lowers the susceptibility to accidental or intentional misuse, including inappropriate routes of administration or chemical tampering.

The disclosed prodrug moieties can include amino acid residues or peptides of up to about 100 amino acids linked via an amide bond to the methadone nitrogen. By selecting promoieties that are substrates for particular enzymes, formulators can adjust release kinetics based on the target enzyme’s activity and distribution. For example, gastrointestinal enzymes like trypsin are contemplated as triggers for prodrug activation. The application also describes including enzyme inhibitors in the pharmaceutical composition to attenuate the rate of enzymatic cleavage when desired. This addition can further control release profiles and reduce unintended rapid activation.

The patent describes general chemical structures of enzyme‑cleavable methadone prodrugs, outlining variations in functional groups and linkers that influence both stability and enzymatic susceptibility. These structures include several formulae (e.g., MD‑(I), MD‑(II), MD‑(III)), each representing different classes of promoieties attached to the methadone core. Notably, upon enzymatic cleavage of the promoiety, a stable cyclic urea or other cyclic group forms, which is pharmaceutically acceptable and of low toxicity. The description also covers pharmaceutically acceptable salts, solvates, and crystalline forms of the prodrugs, enhancing formulation versatility.

A key advantage emphasized in this disclosure is the reduction of excessive plasma methadone levels when the prodrug is administered improperly. Because the prodrug cannot be converted to methadone without specific enzymatic action and cyclization, the risk of overdose is reduced. Furthermore, the document details that trypsin inhibitors or other enzyme modulators may be co‑formulated to regulate the enzymatic activation rate. In addition to the chemical and pharmacokinetic considerations, the application mentions pharmaceutical compositions that include typical excipients, such as fillers, binders, and disintegrants, that support conventional formulation processes for oral delivery.

Use of CELLETS® in This Context

Although CELLETS® (highly spherical microcrystalline cellulose pellets used as starter cores in multiparticulate drug delivery systems) are not explicitly referenced in US20250361205A1, the broader formulation context suggests potential relevance. CELLETS® provide uniform and inert starter cores that support controlled layering of active pharmaceutical ingredients. In multiparticulate systems, CELLETS® improve coating uniformity, flow properties, and controlled release profiles in oral dosage forms. These characteristics make them useful for advanced prodrug formulations where release kinetics and consistency are critical, particularly when precise layering of enzyme‑cleavable prodrug moieties is required. Unlike conventional inert cores, CELLETS® enable predictable performance and facilitate scalable manufacturing for complex oral formulations.

In this patent, some particle sizes of CELLETS® are explicitely named:

Type Particle size distribution
(≥ 85 %)
learn more
CELLETS® 100 100-200 µm
(150/80)
more information
CELLETS® 200 200-355 µm
(80/50)
more information
CELLETS® 350 350-500 µm
(50/35)
more information
CELLETS® 500 500-710 µm
(35/25)
more information
CELLETS® 700 700-1000 µm
(25/18)
more information
CELLETS® 1000 1000-1400 µm
(18/13)
more information

Conclusion and Outlook

In summary, enzyme‑cleavable methadone prodrugs offer a promising advancement in opioid therapy and formulation science, combining controlled enzymatic activation with enhanced safety. The patent US20250361205A1 details chemical constructs and methods that reduce misuse potential and allow sophisticated control of drug release. Given ongoing needs for safer opioid medications, these prodrugs could transform maintenance therapy and pain management by minimizing overdose risks and improving patient compliance. Looking forward, integrating technologies such as multiparticulate delivery systems and optimized excipients (e.g., CELLETS®) will further refine dosing precision and therapeutic outcomes. Future research and clinical evaluation will determine how these designs perform in real‑world settings, including their impact on pharmacokinetics, abuse deterrence, and commercial viability.

Patent Summary

  • Name of Patent: Enzyme-cleavable methadone prodrugs and methods of use thereof
  • Patent Number: US20250361205A1
  • Year of Patent: 2025
  • Patent Holders: Lynn Kirkpatrick
  • Affiliation: Ensysce Biosciences Inc.

Enzyme-cleavable methadone prodrugs Innovations in formulation

cellulose-derived spherical activated carbon

Cellulose-derived spherical activated carbon is a sustainable carbon material made from renewable cellulose sources. It forms uniform spheres with high surface area and excellent porosity after activation. Because of its spherical shape, this carbon flows smoothly, packs efficiently, and resists dust formation. These traits make it ideal for pharmaceutical and biomedical uses. In drug formulation, amorphized amlodipine besylate and hydrochlorothiazide offer exciting potential. Their amorphous states increase solubility, speed up dissolution, and enhance bioavailability. This improvement allows more consistent dosing and better combination therapies. Furthermore, a high-shear granulator helps mix and layer ingredients under controlled energy and moisture. It ensures uniform distribution of amorphous drugs and consistent granule quality, which improves final product performance.

Summary of the Publication

The publication by K. Shin et al [1] introduces an eco-friendly method to create cellulose-derived spherical activated carbon from microcrystalline cellulose. The researchers first carbonized cellulose spheres and then activated them with steam. This process produced strong, uniform carbon spheres with hierarchical pores and high adsorption capacity. The spherical design improved handling and flow compared to traditional irregular carbon particles. Moreover, the material demonstrated high performance in removing uremic toxins in simulated biomedical tests. It showed quick adsorption, strong selectivity, and good stability under different pH and ionic strengths.

Because the raw cellulose originates from renewable sources, this process aligns with circular-economy goals. It also reduces production costs while improving quality and uniformity. The study compared these spherical carbons with conventional activated carbons and found similar or superior adsorption properties. However, the new materials also offered better mechanical strength and shape stability. In addition, the pore size and surface characteristics could be tuned by adjusting activation conditions or cellulose template sizes. This tunability is vital for targeting specific biomedical and environmental applications. Therefore, the study links sustainable material design with real-world medical use.

Use of CELLETS® in the Study

The authors used CELLETS® microcrystalline cellulose spheres as templates to shape the final spherical activated carbon. These CELLETS® provided precise size control and reliable structure during carbonization. As a result, the produced carbon spheres maintained uniform shape, size, and mechanical stability. The templating method allowed predictable performance and made the process suitable for scaling up. In practical terms, this ensured consistent flow, packing, and adsorption performance—essential features in pharmaceutical and medical applications.

Conclusion and Outlook

Cellulose-derived spherical activated carbon offers a major step toward green, high-performance adsorbents. It combines renewable sourcing, excellent flow behavior, and strong adsorption capacity. The integration of CELLETS® templates made production reproducible and efficient. Future work should focus on in-vivo safety, selective adsorption of specific toxins, and process optimization under GMP standards. Furthermore, pairing this carbon material with amorphous APIs like amlodipine besylate and hydrochlorothiazide could lead to multifunctional systems for improved drug delivery and detoxification. As industries move toward sustainability and advanced pharmaceutical technologies, cellulose-derived spherical activated carbon will likely play a central role in next-generation biomedical materials.

References

[1] K. Shin et al., Materials & Design 259 (2025) 114892. doi: 10.1016/j.matdes.2025.114892.

Characterization of Layered Pellets containing amorphized amlodipine besylate and hydrochlorothiazide

Characterization of layered pellets forms the basis of advanced pharmaceutical pellet design. These pellets consist of inert cores coated with active drug layers. Their detailed analysis ensures uniformity, strength, and consistent drug release. Layered systems offer precise dosing, extended or modified release, and taste masking. When the solid-state properties of the drug are modified through amorphization, the pellets can show faster dissolution and better bioavailability. In this study, researchers examined how a high-shear granulator can produce pellets that combine amorphized amlodipine besylate and hydrochlorothiazide, focusing on structure, performance, and stability.

Amlodipine besylate normally appears in a crystalline form with high solubility and a melting point near 200 °C. In contrast, hydrochlorothiazide is poorly soluble and melts near 270 °C. Turning them into an amorphous or co-amorphous form breaks down the crystal lattice, improving solubility and dissolution rate. In co-amorphous systems, the two drugs interact through hydrogen bonding, which stabilizes the amorphous state and prevents recrystallization. This interaction increases the dissolution of both drugs and enhances their bioavailability. The study found that partially amorphized drug mixtures in layered pellets improved release rates while maintaining physical stability.

A high-shear granulator creates these layered systems efficiently. Its strong mechanical forces and controlled heat allow uniform coating and induce amorphization at the same time. Because it works without solvents, this process is clean, fast, and suitable for sensitive compounds.

Summary of the Publication

In the study The Development and Characterization of Layered Pellets Containing a Combination of Amorphized Amlodipine Besylate and Hydrochlorothiazide Using a High-Shear Granulator, Mahmoud et al. [1] developed layered pellets by coating microcrystalline cellulose cores (CELLETS®) with drug mixtures in different molar ratios (2:1, 1:1, 1:2). The high-shear granulator (ProCepT 4M8) operated at 1,500 rpm and 60 °C for three hours. The goal was to achieve partial amorphization and study its impact on dissolution and stability. After preparation, the pellets were stored at –20 °C before testing.

Differential scanning calorimetry showed that amlodipine lost its sharp melting peak, confirming full amorphization. Hydrochlorothiazide retained a broad, weaker peak, meaning it was only partly amorphous. X-ray diffraction supported this: the 2:1 mixture had the lowest crystallinity (26.8 %), while the 1:2 mixture showed the highest (53.6 %). Micro-CT imaging revealed that the drug formed an even layer around the CELLETS® cores. Although some pores appeared, they were inherent to the cores rather than defects from coating.

Texture analysis indicated a small increase in hardness—from 19.8 N for plain CELLETS® to around 21 N for layered pellets—showing the coating slightly strengthened the structure. Dissolution testing showed moderate improvement for amlodipine and a strong improvement for hydrochlorothiazide, with release rates increasing up to 2.6 times. The faster release resulted from reduced crystallinity, improved wettability, and closer contact between drug and medium. FTIR spectra revealed broadening and merging of N–H peaks, confirming new hydrogen bonding and lattice disruption. Stability testing over one month showed that 2:1 and 1:1 ratios stayed mostly amorphous, while the 1:2 mixture recrystallized heavily.

Use of CELLETS® in This Study

The authors used CELLETS®, spherical microcrystalline cellulose cores about 1 mm in size, as the foundation for layering. Their smooth and strong surfaces ensured even coating under high shear. Micro-CT confirmed complete drug coverage and consistent thickness. Moreover, the CELLETS® provided the mechanical strength needed to prevent pellet fracture during processing. Their stable core structure helped maintain uniform shape and resistance to deformation.

Conclusion and Outlook

The study proves that solvent-free high-shear granulation can produce layered pellets with amorphized drug mixtures. The characterization of layered pellets showed lower crystallinity, faster release, and stable structure. Using CELLETS® as cores provided excellent mechanical support. The co-amorphous state of amlodipine and hydrochlorothiazide improved dissolution, especially for the poorly soluble hydrochlorothiazide.

Looking ahead, future research should test long-term stability under stress and evaluate in vivo bioavailability. Scaling the high-shear process could make it viable for industrial use. Furthermore, exploring multi-layer systems or combining more drugs could expand the possibilities of characterization of layered pellets in modern pharmaceutical development.

References

[1] Mahmoud et al., Pharmaceuticals 2025, 18(10), 1496; doi:10.3390/ph18101496

UV Imaging of MUPS Tablets Stability, Functionality, and Outcomes

Introduction to UV Imaging of MUPS Tablets

UV imaging of MUPS tablets (multiple unit pellet system) is a growing field in pharmaceutical research. These tablets combine many coated pellets into one compressed unit. After ingestion, the tablet breaks apart and releases the active pharmaceutical ingredient (API). Researchers explored whether multispectral UV imaging could track the degradation of acetylsalicylic acid (ASA) into salicylic acid (SA). The goal was to confirm that this non-destructive method could monitor stability inside these complex formulations.

Scientific Approach to UV Imaging of MUPS Tablets

The study used CELLETS® 700 as neutral microcrystalline cellulose cores. Scientists layered ASA on these cores and coated them with Eudragit RL PO. They then compressed the pellets into MUPS tablets. The tablets were stored at different temperatures and humidity levels for several months.

At each time point, the tablets were examined with multispectral UV reflectance imaging. This technology captured detailed spectral fingerprints across the surface. To interpret the data, the team applied partial least squares regression (PLS). They predicted the concentration of SA as the main degradation product. High-performance liquid chromatography (HPLC) provided reference values for comparison, ensuring accuracy.

Results of UV Imaging of MUPS Tablets

The outcomes showed that UV imaging worked well for tracking degradation inside the tablets. The predictions matched closely with HPLC results, proving the method’s reliability. Moreover, the technique detected even small amounts of salicylic acid despite the tablet’s protective coating.

Importantly, UV imaging did more than quantify. It created spatial maps that revealed where degradation occurred on the tablet surface. These maps gave new insights into stability that destructive tests could not provide. As a result, the method proved fast, precise, and suitable for quality control and stability studies.

Role of CELLETS® 700 in the Research

CELLETS® 700 played a key role in the experiment. These spherical microcrystalline cellulose pellets range from 700 to 1,000 µm. Their smooth, uniform surface made it easy to apply ASA and coatings evenly. In addition, their chemical stability ensured that imaging signals came only from the coating and degradation layers.

Because CELLETS® 700 are robust, they maintained their structure during compression. This consistency improved the reliability of UV imaging results. Thus, the choice of these pellet cores supported both the technical and analytical goals of the study.

Conclusion

UV imaging of MUPS tablets offers a powerful tool for monitoring stability and degradation. By combining multispectral imaging with statistical modeling, researchers gained accurate and non-destructive insights into tablet quality. CELLETS® 700 provided the structural foundation that made the method effective. Consequently, this approach holds promise as a process-analytical technology for pharmaceutical development and quality assurance.

References

UV imaging of multiple unit pellet system (MUPS) tablets: A case study of acetylsalicylic acid stability
European Journal of Pharmaceutics and Biopharmaceutics, Volume 119, October 2017, Pages 447-453
Anna Novikova, Jens M. Carstensen, Thomas Rades, Claudia S. Leopold

CELLETS® in Malodor Control Compositions

Introduction to Malodor Control Technology

CELLETS® in malodor control compositions mark a new step in odor management. Unpleasant smells from sulfur compounds, volatile organic compounds, aldehydes, and acids are often hard to control. Even more challenging are complex fishy odors that do not come from amines. Traditional solutions often fall short in both efficiency and usability.

The patent application US20250082809, filed by Kalykos LLC, introduces a new approach. It combines high-performance materials with practical handling benefits. As a result, the invention applies across personal care, healthcare, packaging, and industrial products.

The Patent’s Core Innovation

The patent centers on spherical activated carbon particles. These particles have high sphericity, which improves flow, reduces dust, and lowers abrasion. At the same time, they offer large surface areas and strong adsorption capacity. Because of these features, they capture difficult odors more effectively than irregular powders.

The compositions also include active agents such as acids, bases, or odor-neutralizing additives. Manufacturers can coat, spray, immerse, or blend these agents into the particles. This flexibility makes the system suitable for a wide range of products, from diapers and wound dressings to food packaging and air filters. Moreover, the spherical shape supports consistent coatings and safer handling during production.

The Role of CELLETS® in Malodor Control Compositions

A key highlight of this patent is the role of CELLETS®, also known as spherical cellulose particles. Unlike the activated carbon spheres, CELLETS® do not focus on adsorption. Instead, they work as carriers and support agents that improve the overall performance of the formulation.

CELLETS® come from microcrystalline cellulose and form into uniform spheres. Their size can range from 100 to 1400 micrometers. Because of their shape, they flow well, create little dust, and allow even coatings. These features make them valuable in manufacturing and product design.

In this system, CELLETS® can hold coatings of wax or phase change materials. They can also carry odor-control additives and release them in a controlled way (controlled release). Through this role, CELLETS® extend the active life of the carbon-based particles. They also add versatility, since different coatings or agents can adapt the product to specific needs.

When combined, activated carbon particles and CELLETS® create a dual system. The carbon provides strong odor adsorption. The cellulose spheres provide handling benefits, controlled release, and structural support. Together, they deliver a balanced and innovative solution.

Conclusion

The patent offers a major advance in odor control technology. It joins the adsorption strength of spherical carbon with the support and carrier functions of CELLETS®. This combination delivers both performance and usability. CELLETS® in malodor control compositions enhance reliability and open new possibilities for industries that demand effective and adaptable odor solutions.

Delamination and wetting behavior of natural hot-melt coating materials

Hot-melt coating materials improve efficiency and product quality in pharmaceutical and industrial manufacturing. They melt when heated and solidify quickly, forming strong, uniform coatings on various surfaces. As a result, manufacturers reduce production time, lower costs, and avoid using solvents. Furthermore, understanding wetting behavior and delamination is critical to optimize coating performance. For example, CELLETS® 1000 microcrystalline cellulose pellets serve as excellent starter cores, promoting uniform wetting and consistent coating thickness. Consequently, hot-melt coating materials have become a reliable solution for modern manufacturing needs.

Enhancing pharmaceutical and industrial applications by hot-melt coating materials

In the study titled Delamination and Wetting Behavior of Natural Hot-Melt Coating Materials, published in Powder Technology [1], the authors investigated the delamination and wetting behaviors of various natural materials. The research aimed to understand how these materials interact with substrates during the coating process, which is crucial for applications in the pharmaceutical industry. The study utilized laboratory coating experiments and micro-computed tomographic measurements to assess delamination frequency, and a drop shape analyzer to evaluate wetting behavior. Interestingly, the study found no correlation between delamination and wetting behavior, suggesting that other factors may influence delamination in hot-melt coatings.

Among the materials tested, CELLETS® 1000, a type of microcrystalline cellulose (MCC) pellet with a size range between 1000 and 1400 µm, was highlighted for its suitability in hot-melt coating applications. These spherical pellets are known for their chemical inertness, low friability, high sphericity, and smooth surface, making them ideal as starter cores for multiparticulate drug delivery systems. In the context of the study, CELLETS® 1000 demonstrated excellent wetting properties with contact angles ranging from 10° to 18°, which is favorable for uniform coating. However, the study did not find a direct correlation between wetting behavior and delamination, indicating that other factors may play a more significant role in delamination during hot-melt coating processes. Researchers assume that delamination may have resulted from the different thermal expansion coefficients of the carrier particle and the coating material [2]. A change in temperature may have led to thermal stresses and may have promoted spalling or delamination. Subsequent swelling of a hygroscopic carrier material due to moisture could also lead to structural
changes in the coating structure and might cause delamination.

Use of CELLETS® in hot-melt coating processes

The use of CELLETS® in hot-melt coating processes offers several advantages. Their uniform size distribution and smooth surface contribute to consistent coating thickness and quality. Additionally, the chemical inertness of CELLETS® ensures compatibility with a wide range of coating materials, reducing the risk of undesirable interactions. These characteristics make CELLETS® a reliable choice for developing controlled-release formulations and enteric coatings in pharmaceutical applications.

In summary, the study underscores the importance of understanding the delamination and wetting behaviors of natural hot-melt coating materials. While CELLETS® 1000 exhibited favorable wetting properties, the lack of correlation between wetting behavior and delamination suggests that other factors should be considered when selecting materials for hot-melt coating processes. Further research is needed to identify these factors and optimize coating processes for improved product performance.

Understanding Hot-Melt Coating Materials

Hot-melt coating materials are thermoplastic substances that bond effectively to substrates when melted. Their melting point, adhesion properties, and chemical compatibility directly influence coating uniformity and durability. Therefore, selecting the correct material is crucial for minimizing delamination and ensuring product quality. Additionally, their solvent-free nature makes them environmentally friendly and cost-efficient.

Optimizing Coating with CELLETS®

CELLETS® offer significant advantages as starter cores in hot-melt coating processes. Their spherical shape and smooth surface promote uniform wetting and consistent coating thickness. Furthermore, their chemical inertness ensures compatibility with diverse coating materials, reducing the risk of unwanted interactions. Consequently, these MCC spheres support reliable and high-quality coating outcomes in both pharmaceutical and industrial applications.

References

[1] B.M. Wörthmann et al., Powder Technology (404) 2022, 117443; doi: 10.1016/j.powtec.2022.117443.

[2] S. Ebnesajjad, A.H. Landrock, Introduction and adhesion theories, Adhesives Technology, Handbook, 38, Elsevier 2015, pp. 1–18; doi: 10.1016/B978-0-323-35595-7.00001-2.

hydroxynorketamine modified-release dosage form ChatGPT Image 11. Juli 2025, 13_57_57

Introduction

The development of a hydroxynorketamine modified-release dosage form marks an important advance in neuropsychiatric therapy. Hydroxynorketamine (HNK), a ketamine metabolite, shows rapid antidepressant activity through mechanisms different from ketamine itself. It works mainly by modulating α7-nicotinic acetylcholine receptors and activating mTOR pathways.

This targeted action makes HNK a strong candidate as an active pharmaceutical ingredient with a favorable safety profile. Unlike ketamine, it avoids dissociative and addictive side effects. A modified-release form built with CELLETS®—uniform spherical pellets—offers tighter therapeutic control. It sustains plasma concentration, reduces peak-to-trough swings, and helps patients stay consistent with treatment.

In addition, the inert cores often range between 100 and 500 μm in size. A more refined range of 200 to 400 μm improves precision. About 90% of particles fall within this window, confirmed by sieve analysis. One example is CELLETS® 200, which demonstrates this particle size distribution effectively.

API Function and Patient Benefits

Hydroxynorketamine mainly acts by inhibiting α7-nicotinic receptors. This lowers intracellular Ca²⁺ and D-serine levels and reduces NMDA receptor excitotoxicity. At the same time, it boosts mTOR signaling and strengthens AMPA receptor function.

Together, these effects speed up synaptogenesis and create fast antidepressant responses. Evidence comes from both preclinical studies and early clinical findings. For patients, this means rapid mood elevation without ketamine-related side effects. Unlike ketamine, it does not cause hallucinations or carry strong abuse potential.

From a pharmacokinetic view, a modified-release dosage form improves consistency in therapy. It also simplifies dosing schedules and increases tolerability.

Modified‑release dosage Formulation with CELLETS®

The incorporation of CELLETS® into the modified‑release formulation provides several benefits. Their uniform size and high sphericity ensure consistent drug coating and predictable release. CELLETS® also enable multiparticulate dosing, which reduces variability and allows tailored release profiles.

For hydroxynorketamine (HNK), CELLETS® can carry specific polymer coatings such as ethylcellulose or Eudragit. These coatings dissolve or erode at controlled rates, releasing the API steadily over time. This method lowers peak systemic concentrations, which reduces side effects while maintaining efficacy.

Additionally, CELLETS® support monolithic layering or reservoir systems. This setup allows complex release patterns, such as an initial burst followed by sustained delivery. Such profiles are ideal for achieving a rapid onset and maintaining antidepressant effects in depression treatment.

Key Findings on Hydroxynorketamine modified‑release dosage form

In the disclosed patent (US 2025 0177325 A1), researchers describe a multiparticulate modified‑release system for hydroxynorketamine. They use CELLETS® as the core substrate. The CELLETS® carry successive polymer layers that control drug release. This design produces an initial release phase followed by prolonged delivery.

Pharmacokinetic modeling shows a flattened plasma-concentration profile, lower maximum concentration (Cmax), longer time to peak (Tmax), and higher area under the curve (AUC). Together, these factors maintain therapeutic HNK levels over time. This steady exposure may reduce rebound symptoms and cut dosing frequency. As a result, patient adherence improves, and treatment regimens may shift to once-daily or even less frequent dosing.

Conclusion and Outlook

In conclusion, the hydroxynorketamine modified‑release dosage form using CELLETS® offers a promising pharmaceutical approach. It leverages HNK’s unique mechanism as a non-dissociative antidepressant. Controlled release maximizes its clinical potential.

Cellet-based formulations improve pharmacokinetics, enhance tolerability, and increase convenience. These benefits could significantly help patients with treatment-resistant depression. Further work is needed, including in vitro−in vivo correlation studies, polymer selection optimization, and confirmatory clinical trials.

Looking ahead, this technology may expand HNK applications to other neuropsychiatric or neurodegenerative disorders. It provides a refined dosage form that meets both patient needs and therapeutic goals.

Patent Details

  • Name or patent: Hydroxynorketamine for the use in the treatment of depression
  • Patent number: US 20250177325 A1
  • Year of patent: 2025
  • Patent holder names and affiliation: (Names not specified in public abstract; likely the inventors assigned to their sponsoring institution or company as listed in patent document)

This summary underscores the innovative use of CELLETS® in creating a refined hydroxynorketamine modified-release dosage form that elevates both therapeutic performance and patient-centric outcomes.

hydroxynorketamine modified-release dosage form
US20250186377A1 cellet‑based modified‑release gamma‑hydroxybutyrate formulation ChatGPT Image 11. Juli 2025, 13_12_09

Introduction

Gamma‑hydroxybutyrate (GHB) is an endogenous neurotransmitter also used pharmaceutically—usually as sodium oxybate—for treating narcolepsy and related disorders. It exerts its therapeutic effects by modulating GABA_B receptors and promoting slow-wave sleep, alleviating cataplexy, and reducing excessive daytime sleepiness. Despite its efficacy, current twice-nightly dosing regimens present challenges: dose‑dumping in the presence of alcohol, variable pharmacokinetics depending on food intake, and patient inconvenience. To address these issues, modern formulations—and especially the innovative use of CELLETS® —pursue once-nightly controlled release.

API Benefits and Patient Advantages

Administering gamma‑hydroxybutyrate compositions in a modified‑release format brings multiple patient-centric benefits. A single nightly dose minimizes repeated nighttime awakenings and improves adherence. These formulations exhibit lower peak concentrations (C_max) with sustained therapeutic exposure (AUC)—achieving similar or better efficacy while reducing adverse events such as dizziness or nausea. This consistency is especially meaningful when dosing less than two hours after eating, which often is more convenient for patients; the controlled formulations are more forgiving of fed-state PK variability and less prone to alcohol-induced dose-dumping.

Use of CELLETS® in methods of administering gamma-hydroxybutyrate compositions

CELLETS® — spherical microcores used in multiparticulate drug delivery—are central to these modern GHB formulations. The patent US 20250186377 A1 introduces coated cellet-based microparticles that incorporate immediate-release (IR) and modified-release (MR) segments within a single unit dose. The MR portion involves CELLETS® (e.g. CELLETS® 90, CELLETS® 100 or CELLETS® 127, and other MCC beads) coated with polymers carrying free carboxyl groups combined with hydrophobic materials (e.g., high melting point waxes), engineered to delay GHB release until intestinal transit. CELLETS® enable precise layering, efficient coating, and reproducible drug release profiles while resisting pH- and alcohol-triggered dose dumping.

This multiparticulate approach achieves desired PK: IR CELLETS® ensure rapid onset while MR CELLETS® sustain plasma GHB levels up to 8 hours. In contrast to IR liquid sodium oxybate, the coated cellet formulation shows dose‑proportional C_max and AUC across doses of 4.5 g, 7.5 g, and 9 g, with most AEs clustering near C_max but at overall milder intensity. Remarkably, cellet-based formulations maintain comparable therapeutic exposure even with postprandial dosing, offering flexibility not seen in immediate-release forms.

Key Findings

The inventive cellet-based GHB composition delivers both immediate and controlled drug release in one unit, offering dose‑proportional pharmacokinetics and sustained therapeutic levels for 8 hours, under single-nightly dosing. It improves safety by reducing peak‑induced adverse events, lowers risk of alcohol‑related dose-dumping, and allows dosing within two hours after meals. Studies show comparable efficacy to twice-nightly IR sodium oxybate on sleep quality and daytime alertness, with better convenience and adherence.

Conclusion & Outlook

The patented cellet‑based modified-release formulation of GHB marks a significant advancement in administering gamma‑hydroxybutyrate compositions. By incorporating coated CELLETS® that combine IR and MR elements, this approach mitigates common limitations—meal dependency, alcohol interactions, multiple nightly doses—while preserving therapeutic efficacy. For patients with narcolepsy or cataplexy, this translates into improved sleep continuity, reduced daytime symptoms, and enhanced quality of life.

Looking ahead, further clinical evaluation could extend the CELLETS® platform to other formulations of gamma‑hydroxybutyrate salts or co‑therapies (e.g., with sodium valproate), further broadening the therapeutic utility. This modular, multiparticulate delivery system could set a new standard for nightly dosing regimens where controlled pharmacokinetics and patient preferences align.

Patent Details

  • Name/Title: cellet‑based modified‑release gamma‑hydroxybutyrate formulation

  • Patent Number: US 20250186377 A1

  • Year of Patent: 2025

  • Patent Holder(s): Not explicitly indicated in the publicly listed data, but associated inventors likely affiliated with pharmaceutical firms focusing on CNS therapeutics (e.g., Jazz Pharmaceuticals or Flamel Ireland).
US20250186377A1 cellet‑based modified‑release gamma‑hydroxybutyrate formulation ChatGPT Image 11. Juli 2025, 13_12_09